(Q36150595)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15934864%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

review article

1 reference

title

Reactivation of hepatitis B virus with rituximab (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15934864%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15934864%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

author name string

Yutaka Tsutsumi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15934864%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Hiroe Kanamori

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15934864%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Akio Mori

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15934864%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Junji Tanaka

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15934864%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Masahiro Asaka

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15934864%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Masahiro Imamura

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15934864%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

language of work or name

English

0 references

publication date

1 May 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15934864%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Safety

12 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15934864%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15934864%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15934864%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

599-608

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15934864%20AND%20SRC:MED&resulttype=core&format=json

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy

12 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

New treatment approaches to indolent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Efficacy of Lamivudine in patients with hematologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Transcriptional and posttranscriptional control of hepatitis B virus gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

Hepatitis B infection in patients with lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.599

21 January 2018

Identifiers

DOI

10.1517/14740338.4.3.599

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15934864%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference